Last reviewed: July 2026 · Reviewed annually · Applies to ivjournal.com and all IV Journal content
This policy explains how IV Journal handles advertising and sponsored content, in line with ICMJE recommendations and the DOAJ/COPE/OASPA/WAME Principles of Transparency (clause 15).
It applies to all forms of commercial content on IV Journal, including display advertising, in-article placements, and sponsored articles, and is intended to protect the independence and integrity of our editorial and peer review process.
IV Journal accepts display advertising and sponsorship from relevant commercial and professional organisations. Advertising revenue supports our Diamond Open Access model, allowing us to publish free of charge for both authors and readers.
Acceptance of advertising does not imply IV Journal's endorsement of any product, service, or organisation, and all advertising is subject to the restrictions set out in this policy.
We consider a range of formats, subject to review by our editorial team.
This list is not exhaustive. The Editor-in-Chief may decline any advertisement at their discretion, even where it is not explicitly listed above.
The Editor-in-Chief holds final authority over all advertising and sponsorship decisions, including which advertisements are accepted, declined, or removed.
Commercial and advertising staff are kept separate from editorial decision-making. The commercial team cannot approve, override, or influence editorial or peer review decisions, and editorial staff have no role in negotiating advertising terms.
Where an advertising or sponsorship arrangement is agreed, the Editor-in-Chief is notified in advance of publication.
Advertisements are served at random across the site and are not linked or targeted to the content of any specific article, author, or search term.
We do not knowingly place an advertisement for a product or service directly alongside an article discussing that same product or service.
Where relevant, advertising may be rotated according to broad subject tags (for example, vascular access or infection prevention) rather than individual articles, to help ensure relevance without compromising independence.
IV Journal occasionally publishes sponsored content, such as sponsored articles or features, commissioned and paid for by a commercial organisation.
Sponsored content is not part of the scholarly record. It is not assigned a DOI, is not registered with Crossref or indexed by DOAJ, and does not carry a volume, issue, or citation metrics.
Sponsored content may be authored by the sponsor, by IV Journal on the sponsor's behalf, or jointly, but final editorial control over tone, accuracy, and compliance with this policy rests with IV Journal.
Payment for sponsored content covers editorial support, production, and placement. It does not purchase editorial approval of claims that cannot be supported by evidence.
Sponsored content is priced according to our rate card and remains live for an agreed duration. If a factual error is identified after publication, IV Journal will correct or, where necessary, remove the content.
Advertising and sponsorship have no influence on which manuscripts are accepted, on the outcome of peer review, or on the editorial content of any article.
No advertiser or sponsor is given advance sight of, influence over, or approval rights on unrelated editorial content.
Where advertising relates to healthcare products or services aimed at UK audiences, it must comply with the UK Committee of Advertising Practice (CAP) Code for non-broadcast advertising.
Where advertising relates to pharmaceutical products, it must additionally comply with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice.
See: UK CAP Code and ABPI Code of Practice.
If you have a concern about an advertisement or sponsored content on IV Journal, please contact us at team@ivteam.com.
We aim to acknowledge all advertising complaints within 5 working days.
Where a complaint cannot be resolved directly, it may be escalated to the Advertising Standards Authority (ASA) or, for pharmaceutical advertising, the Prescription Medicines Code of Practice Authority (PMCPA).
This policy is reviewed annually by the Editor-in-Chief to ensure it remains consistent with ICMJE recommendations, DOAJ transparency principles, and relevant UK advertising regulation.
If anything in this policy is unclear, or you'd like to discuss an advertising or sponsorship arrangement, our team is happy to help.